¼¯ÃÀÂ鶹

————————————-

The human genome is the fundamental blueprint of life. It holds the biological information that shapes human development, influences health and disease, and determines how individuals respond to treatment, environment, and lifestyle. In recent years, advances in genomics have transformed medicine by making it possible to better understand why some individuals are more susceptible to certain diseases, why treatments work well for some but not others, and how prevention and care can be tailored more precisely. This is the promise of precision medicine and precision health: delivering the right intervention to the right person at the right time, based on a deeper understanding of biology, environment, and lifestyle.

Globally, this transformation has been driven by landmark initiatives such as the Human Genome Project, the UK Biobank, the All of US Research Program in the United States, Singapore’s National Precision Medicine Programme, and the Human Pangenome Reference Consortium. These initiatives have demonstrated that genomic resources are no longer merely scientific undertakings; they are strategic national assets that strengthen research capacity, accelerate innovation, and shape the future of healthcare systems.

Yet one important lesson has become increasingly clear: no single reference genome can fully represent the diversity of all human populations. Earlier reference genomes, while foundational, were built from a limited representation of populations and do not adequately capture the full spectrum of variation across different ancestries. This has important implications for diagnosis, risk prediction, pharmacogenomics, and the interpretation of genomic data. This matters because genomic differences influence disease risk, drug response, diagnosis, and the interpretation of genetic tests. For this reason, countries are increasingly building their own reference genomes or pangenomes that better reflect the unique characteristics of their populations. For Malaysia, a nation distinguished by remarkable ethnic, cultural, and ancestral diversity, such a resource is both scientifically necessary and nationally significant.

The Malaysian Pangenome was developed from this global scientific understanding and from Malaysia’s own long-term investment in population research through The Malaysian Cohort (TMC). Established as a national project, with the ¼¯ÃÀÂ鶹 Medical Molecular Biology (UMBI) as the custodian, The Malaysian Cohort has built one of the country’s most valuable biomedical research resources, with extensive epidemiological, clinical, and biospecimen data to support the study of gene-environment interactions, disease risk, and population health. Building on this national resource, the Malaysian Pangenome was conceived to provide a genomic reference that truly reflects the diversity of the Malaysian population and supports the country’s ambitions in precision health.

The Malaysian Pangenome comprises more than 4,000 genomes, generated through a combination of short-read, long-read, and telomere-to-telomere (T2T) sequencing technologies, representing 56 ethnic groups from Malaysia’s rich and diverse population. This is a landmark scientific achievement. It establishes one of the most important national genomic resources ever assembled in the country. By capturing the diversity of populations across Malaysia, the database provides a far more relevant foundation for genomic discovery, variant interpretation, and future clinical translation. It also helps address a major gap in global genomic resources, where Southeast Asian populations have historically been underrepresented.

The impact of this resource will be far-reaching. It provides a critical foundation for downstream applications in disease gene discovery, variant interpretation, population health research, risk prediction, biomarker development, pharmacogenomics, diagnostics, and the development of more precise preventive and therapeutic strategies. It can improve the accuracy of genetic interpretation for Malaysians, support the development of tests and tools better suited to local populations, and accelerate research into major health priorities such as cancer, cardiovascular disease, diabetes, rare disorders, and other complex conditions. At the same time, it strengthens Malaysia’s position as an active contributor to regional and global genomic science.

Looking to the future, the Malaysian Pangenome represents not only a scientific milestone, but a strategic national platform for the advancement of healthcare, research, and innovation. It will serve as a foundation for deeper integration of genomics into healthcare, research, and policy. Its future lies not only in expanding the resource, but also in translating knowledge into better outcomes for patients and populations — enabling healthcare that is more precise, more effective, more equitable, and ultimately more impactful for Malaysia and the region.

Lead investigator
Professor Datuk Dr. A Rahman A Jamal

Team members:
Dr. Muhammad Redha Abdullah Zawawi
Dr. Noraidatulakma Abdullah @ Muda
Ts. Muhiddin Ishak
Nazihah Abd Jalal
Nur Alyaa Afifah Md Shahri
Amalia Natasya Saiful Amri
Khoo Jia Shiun